Biotech Gainers: Fate Therapeutics Inc (NASDAQ:FATE), ZIOPHARM Oncology (NASDAQ:ZIOP), Uniqure NV (NASDAQ:QURE), Sorrento Therapeutics (NASDAQ:SRNE)

Fate Therapeutics Inc (NASDAQ:FATE) recently issued a statement that it has enrolled it first patient for the second phase of this study. The primary aim of the PUMA study is to assess the efficacy and safety of PROHEMA in a randomized, controlled environment for patients that are under treatment for hematopoietic stem cell or HSC transplantation for hematologic malignancies. Fate Therapeutics Inc (NASDAQ:FATE) stock performance was 5.24% in last session and finished the day at $11.65. Traded volume was 29,578 million shares in the last session and the average volume of the stock remained 43.07 million shares. Fate Therapeutics Inc (NASDAQ:FATE) insider ownership is 1.20%.

Clinical-stage biopharmaceutical company ZIOPHARM Oncology (NASDAQ:ZIOP) jumped 11.8% following a rating initiation from Mizuho Financial Group. Mizuho, in a research note released last night, started ZIOPHARM with a buy rating and an $11 price target, implying 127% potential upside based on yesterday’s close. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) rose 11.75 percent to $5.42 yesterday on volume of 3.42 million shares. The intra-day range of the stock was $5.15 to $5.58. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) has a market capitalization of $545.02 million.

uniQure NV (NASDAQ:QURE) and Chiesi Farmaceutici announced initial analysis of retrospectively collected individual patient data from LPLD patients treated with Glybera. The analysis covers follow-up data for up to six years post treatment for 13 patients, all of whom met indication requirements for the current labeling of Glybera in the EU. Uniqure NV (NASDAQ:QURE)’s stock on Mar20, 2014 reported an increase of 5.03% to the closing price of $16.79. Its fifty two weeks range is $13.10 -$18.75. The total market capitalization recorded $282.06 million. The overall volume in the last trading session was 115,062 million shares. In its share capital, Uniqure NV (NASDAQ:QURE) has 273.64 million outstanding shares.

Sorrento Therapeutics, Inc (NASDAQ:SRNE) intends to conduct meetings with third parties in which its corporate slide presentation will be presented. The Company’s presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K. On Thursday, shares of Sorrento Therapeutics Inc (NASDAQ:SRNE) advanced 9.72% to close the day at $15.91. Company return on investment (ROI) is -77.40% and its monthly performance is recorded as 62.51%. Sorrento Therapeutics Inc (NASDAQ:SRNE) quarterly revenue growth is 69.44%.